1-20 of 21
Joan Albanell
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract P2-12-27: A phase Ib study of the safety, tolerability, biological effect, and efficacy of allogenic natural killer cells in combination with trastuzumab and pertuzumab in patients with refractory HER2-positive metastatic breast cancer

Free
Santiago Escrivá-de-Romaní, Vladimir Galvao, Maria Castro-Henriques, Ascensión Lopez-Díaz de Cerio, Aura Muntasell, Carlos Vilches, Miguel López-Botet, Maria del Carmen Ochoa, Susana Inmaculada Inoges, Sara Santana, Marta Rotxes, Pere Barba, Julia Lostes, Gabriela Ene, Sonia Servitja, Guillermo Villacampa, Susana Muñoz, Darío López, Xenia Villalobos, Silvia Martin Lluesma, Cristina Saura, Joan Albanell, Elena Garralda, Ignacio Melero, Maria Martinez-Garcia
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (12_Supplement): P2-12-27.
https://doi.org/10.1158/1557-3265.SABCS24-P2-12-27
Published: 13 June 2025
View articletitled, Abstract P2-12-27: A phase Ib study of the safety, tolerability, biological effect, and efficacy of allogenic natural killer cells in combination with trastuzumab and pertuzumab in patients with refractory HER2-positive metastatic breast cancer
Journal Articles

Abstract P2-07-29: DNADX in advanced hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer following endocrine therapy with or without palbociclib: a correlative analysis from the GEICAM/2014-12 FLIPPER phase II randomized trial

Free
Joan Albanell, Aleix Prat, Maria Teresa Martinez, Guillermo Villacampa, Lorena Paris, Sandra Cobo, Miriam O' Connor, Rosario Vega, Luis de la Cruz-Merino, Fara Brasó-Maristany, Ana Santaballa Bertrán, Francisco Pardo, Noelia Martínez-Jañez, Patricia Galván, Fernando Moreno, Oleguer Castillo, Isaura Fernández, Laia Paré, Jesús Alarcón, Judit Matito, Juan Antonio Virizuela, Juan de la Haba-Rodríguez, Pedro Sánchez-Rovira, Lucía González-Cortijo, Mireia Margelí, Alfonso Sánchez-Muñoz, Iria González Maeso, Antonio Antón, Juan Guerra, Ariadna Tibau, Manuel Ruíz-Borrego, Cinta Rosa Albacar, Coralia Bueno, Andrés García-Palomo, Yolanda Fernández, Sonia González, María Rodríguez de la Borbolla, Vega Iranzo, Catherine M Kelly, Maccon M Keane, Patrick G Morris, Conleth G Murphy, Charles M Perou, Jesús Herranz, Joel S Parker, Marta Portela, Patricia Villagrasa, Rosalia Caballero, Ana Vivancos, Federico Rojo
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (12_Supplement): P2-07-29.
https://doi.org/10.1158/1557-3265.SABCS24-P2-07-29
Published: 13 June 2025
View articletitled, Abstract P2-07-29: DNADX in advanced hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer following endocrine therapy with or without palbociclib: a correlative analysis from the GEICAM/2014-12 FLIPPER phase II randomized trial
Journal Articles

Palbociclib Rechallenge for Hormone Receptor–Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial

Open Access
Joan Albanell, José Manuel Pérez-García, Miguel Gil-Gil, Giuseppe Curigliano, Manuel Ruíz-Borrego, Laura Comerma, Joan Gibert, Meritxell Bellet, Begoña Bermejo, Lourdes Calvo, Juan de la Haba, Enrique Espinosa, Alessandro Marco Minisini, Vanesa Quiroga, Ana Santaballa Bertran, Leonardo Mina, Beatriz Bellosillo, Federico Rojo, Silvia Menéndez, Miguel Sampayo-Cordero, Crina Popa, Andrea Malfettone, Javier Cortés, Antonio Llombart-Cussac
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (1): 67–80.
https://doi.org/10.1158/1078-0432.CCR-22-1281
Published: 04 January 2023
View articletitled, Palbociclib Rechallenge for Hormone Receptor–Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial
Open the PDF for Palbociclib Rechallenge for Hormone Receptor–Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial in another window
Includes: Supplementary data
Journal Articles

Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer

Available to Purchase
Cristina Guardia, Giampaolo Bianchini, Oriol Arpí-LLucià, Silvia Menendez, David Casadevall, Barbara Galbardi, Matteo Dugo, Sonia Servitja, Juan Carlos Montero, Luis Soria-Jiménez, MohammadA Sabbaghi, Raul Peña, Juan Madoz-Gúrpide, Belen Lloveras, Ana Lluch, Pilar Eroles, Joaquin Arribas, Atanasio Pandiella, Luca Gianni, Federico Rojo, Ana Rovira, Joan Albanell
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (18): 5096–5108.
https://doi.org/10.1158/1078-0432.CCR-20-2915
Published: 15 September 2021
View articletitled, Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer
Open the PDF for Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

In Memoriam: José Baselga's Journey in Cancer Medicine

Free
Rakesh Kumar, Gabriel N. Hortobagy, Joan Albanell, Joaquín Arribas, Larry Norton
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (12): 3499–3502.
https://doi.org/10.1158/1078-0432.CCR-21-1624
Published: 15 June 2021
View articletitled, In Memoriam: José Baselga's Journey in Cancer Medicine
Open the PDF for In Memoriam: José Baselga's Journey in Cancer Medicine in another window
Journal Articles

Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation

Available to Purchase
Patricia Fernández-Nogueira, Mario Mancino, Gemma Fuster, Anna López-Plana, Patricia Jauregui, Vanesa Almendro, Estel Enreig, Silvia Menéndez, Federico Rojo, Aleix Noguera-Castells, Anke Bill, L. Alex Gaither, Laia Serrano, Leire Recalde-Percaz, Núria Moragas, Raul Alonso, Elisabet Ametller, Ana Rovira, Ana Lluch, Joan Albanell, Pere Gascon, Paloma Bragado
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (6): 1432–1448.
https://doi.org/10.1158/1078-0432.CCR-19-0353
Published: 13 March 2020
View articletitled, Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation
Open the PDF for Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation in another window
Includes: Supplementary data
Journal Articles

NK Cell Infiltrates and HLA Class I Expression in Primary HER2+ Breast Cancer Predict and Uncouple Pathological Response and Disease-free Survival

Free
Aura Muntasell, Federico Rojo, Sonia Servitja, Carlota Rubio-Perez, Mariona Cabo, David Tamborero, Marcel Costa-García, María Martínez-Garcia, Sílvia Menéndez, Ivonne Vazquez, Ana Lluch, Abel Gonzalez-Perez, Ana Rovira, Miguel López-Botet, Joan Albanell
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (5): 1535–1545.
https://doi.org/10.1158/1078-0432.CCR-18-2365
Published: 01 March 2019
View articletitled, NK Cell Infiltrates and HLA Class I Expression in Primary HER2+ Breast Cancer Predict and Uncouple Pathological Response and Disease-free Survival
Open the PDF for NK Cell Infiltrates and HLA Class I Expression in Primary HER2+ Breast Cancer Predict and Uncouple Pathological Response and Disease-free Survival in another window
Includes: Supplementary data
Journal Articles

First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors

Free
Manuel Hidalgo, Maria Martinez-Garcia, Christophe Le Tourneau, Christophe Massard, Elena Garralda, Valentina Boni, Alvaro Taus, Joan Albanell, Marie-Paule Sablin, Marie Alt, Ratislav Bahleda, Andrea Varga, Christophe Boetsch, Izolda Franjkovic, Florian Heil, Angelika Lahr, Katharina Lechner, Anthony Morel, Tapan Nayak, Simona Rossomanno, Kevin Smart, Kay Stubenrauch, Oliver Krieter
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (7): 1536–1545.
https://doi.org/10.1158/1078-0432.CCR-17-1588
Published: 02 April 2018
View articletitled, First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors
Open the PDF for First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer

Free
MohammadA Sabbaghi, Gabriel Gil-Gómez, Cristina Guardia, Sonia Servitja, Oriol Arpí, Sara García-Alonso, Silvia Menendez, Montserrat Arumi-Uria, Laia Serrano, Marta Salido, Aura Muntasell, Maria Martínez-García, Sandra Zazo, Cristina Chamizo, Paula González-Alonso, Juan Madoz-Gúrpide, Pilar Eroles, Joaquin Arribas, Ignasi Tusquets, Ana Lluch, Atanasio Pandiella, Federico Rojo, Ana Rovira, Joan Albanell
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (22): 7006–7019.
https://doi.org/10.1158/1078-0432.CCR-17-0696
Published: 14 November 2017
View articletitled, Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer
Open the PDF for Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

A PAM50-Based Chemoendocrine Score for Hormone Receptor–Positive Breast Cancer with an Intermediate Risk of Relapse

Free
Aleix Prat, Ana Lluch, Arran K. Turnbull, Anita K. Dunbier, Lourdes Calvo, Joan Albanell, Juan de la Haba-Rodríguez, Angels Arcusa, José Ignacio Chacón, Pedro Sánchez-Rovira, Arrate Plazaola, Montserrat Muñoz, Laia Paré, Joel S. Parker, Nuria Ribelles, Begoña Jimenez, Abdul Aziz Bin Aiderus, Rosalía Caballero, Barbara Adamo, Mitch Dowsett, Eva Carrasco, Miguel Martín, J. Michael Dixon, Charles M. Perou, Emilio Alba
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (12): 3035–3044.
https://doi.org/10.1158/1078-0432.CCR-16-2092
Published: 14 June 2017
View articletitled, A PAM50-Based Chemoendocrine Score for Hormone Receptor–Positive Breast Cancer with an Intermediate Risk of Relapse
Open the PDF for A PAM50-Based Chemoendocrine Score for Hormone Receptor–Positive Breast Cancer with an Intermediate Risk of Relapse in another window
Includes: Supplementary data
Journal Articles

The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer

Free
Francisco J. Sánchez-Martín, Beatriz Bellosillo, Mariona Gelabert-Baldrich, Alba Dalmases, Israel Cañadas, Joana Vidal, Alejandro Martinez, Guillem Argilés, Giulia Siravegna, Sabrina Arena, Klaus Koefoed, Laura Visa, Oriol Arpí, Ivan David Horak, Mar Iglesias, Christopher Stroh, Michael Kragh, Ana Rovira, Joan Albanell, Josep Tabernero, Alberto Bardelli, Clara Montagut
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (13): 3260–3267.
https://doi.org/10.1158/1078-0432.CCR-15-2400
Published: 30 June 2016
View articletitled, The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer
Open the PDF for The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer

Free
Sabrina Arena, Beatriz Bellosillo, Giulia Siravegna, Alejandro Martínez, Israel Cañadas, Luca Lazzari, Noelia Ferruz, Mariangela Russo, Sandra Misale, Iria González, Mar Iglesias, Elena Gavilan, Giorgio Corti, Sebastijan Hobor, Giovanni Crisafulli, Marta Salido, Juan Sánchez, Alba Dalmases, Joaquim Bellmunt, Gianni De Fabritiis, Ana Rovira, Federica Di Nicolantonio, Joan Albanell, Alberto Bardelli, Clara Montagut
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (9): 2157–2166.
https://doi.org/10.1158/1078-0432.CCR-14-2821
Published: 30 April 2015
View articletitled, Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer
Open the PDF for Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Targeting Epithelial-to-Mesenchymal Transition with Met Inhibitors Reverts Chemoresistance in Small Cell Lung Cancer

Free
Israel Cañadas, Federico Rojo, Álvaro Taus, Oriol Arpí, Montserrat Arumí-Uría, Lara Pijuan, Silvia Menéndez, Sandra Zazo, Manuel Dómine, Marta Salido, Sergi Mojal, Antonio García de Herreros, Ana Rovira, Joan Albanell, Edurne Arriola
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (4): 938–950.
https://doi.org/10.1158/1078-0432.CCR-13-1330
Published: 16 February 2014
View articletitled, Targeting Epithelial-to-Mesenchymal Transition with Met Inhibitors Reverts Chemoresistance in Small Cell Lung Cancer
Open the PDF for Targeting Epithelial-to-Mesenchymal Transition with Met Inhibitors Reverts Chemoresistance in Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors

Free
Maria Martinez-Garcia, Udai Banerji, Joan Albanell, Rastilav Bahleda, Saoirse Dolly, Françoise Kraeber-Bodéré, Federico Rojo, Emilie Routier, Ernesto Guarin, Zhi-Xin Xu, Ruediger Rueger, Jean J. L. Tessier, Eliezer Shochat, Steve Blotner, Valerie Meresse Naegelen, Jean-Charles Soria
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (17): 4806–4819.
https://doi.org/10.1158/1078-0432.CCR-12-0742
Published: 30 August 2012
View articletitled, First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors
Open the PDF for First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Pharmacodynamic Trial of Nimotuzumab in Unresectable Squamous Cell Carcinoma of the Head and Neck: A SENDO Foundation Study

Free
Federico Rojo, Elías Gracias, Nadia Villena, Teresa Cruz, Josep Maria Corominas, Irene Corradino, Mercedes Cedeño, Clara Campas, Marta Osorio, Normando Iznaga, Beatriz Bellosillo, Ana Rovira, Silvia Marsoni, Pere Gascon, Sergio Serrano, Cristiana Sessa, Tania Crombet, Joan Albanell
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (8): 2474–2482.
https://doi.org/10.1158/1078-0432.CCR-09-3042
Published: 14 April 2010
View articletitled, Pharmacodynamic Trial of Nimotuzumab in Unresectable Squamous Cell Carcinoma of the Head and Neck: A SENDO Foundation Study
Open the PDF for Pharmacodynamic Trial of Nimotuzumab in Unresectable Squamous Cell Carcinoma of the Head and Neck: A SENDO Foundation Study in another window
Journal Articles

Mitogen-Activated Protein Kinase Phosphatase-1 in Human Breast Cancer Independently Predicts Prognosis and Is Repressed by Doxorubicin

Free
Federico Rojo, Irene González-Navarrete, Rafael Bragado, Alba Dalmases, Silvia Menéndez, Maria Cortes-Sempere, Cristina Suárez, Cristina Oliva, Sonia Servitja, Vanesa Rodriguez-Fanjul, Isabel Sánchez-Pérez, Clara Campas, Josep Maria Corominas, Ignasi Tusquets, Beatriz Bellosillo, Sergi Serrano, Rosario Perona, Ana Rovira, Joan Albanell
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (10): 3530–3539.
https://doi.org/10.1158/1078-0432.CCR-08-2070
Published: 18 May 2009
View articletitled, Mitogen-Activated Protein Kinase Phosphatase-1 in Human Breast Cancer Independently Predicts Prognosis and Is Repressed by Doxorubicin
Open the PDF for Mitogen-Activated Protein Kinase Phosphatase-1 in Human Breast Cancer Independently Predicts Prognosis and Is Repressed by Doxorubicin in another window
Journal Articles

A Phase I Study of the Safety and Pharmacokinetics of the Combination of Pertuzumab (rhuMab 2C4) and Capecitabine in Patients with Advanced Solid Tumors

Free
Joan Albanell, Clara Montagut, Eileen T. Jones, Linda Pronk, Begoña Mellado, Janette Beech, Pere Gascon, Gerhard Zugmaier, Michael Brewster, Mark P. Saunders, Juan W. Valle
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (9): 2726–2731.
https://doi.org/10.1158/1078-0432.CCR-07-1980
Published: 01 May 2008
View articletitled, A Phase I Study of the Safety and Pharmacokinetics of the Combination of Pertuzumab (rhuMab 2C4) and Capecitabine in Patients with Advanced Solid Tumors
Open the PDF for A Phase I Study of the Safety and Pharmacokinetics of the Combination of Pertuzumab (rhuMab 2C4) and Capecitabine in Patients with Advanced Solid Tumors in another window
Journal Articles

Interleukin 6, a Nuclear Factor-κB Target, Predicts Resistance to Docetaxel in Hormone-Independent Prostate Cancer and Nuclear Factor-κB Inhibition by PS-1145 Enhances Docetaxel Antitumor Activity

Free
Josep Domingo-Domenech, Cristina Oliva, Ana Rovira, Jordi Codony-Servat, Marta Bosch, Xavier Filella, Clara Montagut, Marian Tapia, Clara Campás, Lenny Dang, Mark Rolfe, Jeffrey S. Ross, Pere Gascon, Joan Albanell, Begoña Mellado
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (18): 5578–5586.
https://doi.org/10.1158/1078-0432.CCR-05-2767
Published: 25 September 2006
View articletitled, Interleukin 6, a Nuclear Factor-κB Target, Predicts Resistance to Docetaxel in Hormone-Independent Prostate Cancer and Nuclear Factor-κB Inhibition by PS-1145 Enhances Docetaxel Antitumor Activity
Open the PDF for Interleukin 6, a Nuclear Factor-κB Target, Predicts Resistance to Docetaxel in Hormone-Independent Prostate Cancer and Nuclear Factor-κB Inhibition by PS-1145 Enhances Docetaxel Antitumor Activity in another window
Journal Articles

p95HER-2 Predicts Worse Outcome in Patients with HER-2-Positive Breast Cancer

Free
Rosana Sáez, Miguel A. Molina, Elizabeth E. Ramsey, Federico Rojo, Edward J. Keenan, Joan Albanell, Ana Lluch, Javier García-Conde, José Baselga, Gail M. Clinton
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (2): 424–431.
https://doi.org/10.1158/1078-0432.CCR-05-1807
Published: 20 January 2006
View articletitled, p95HER-2 Predicts Worse Outcome in Patients with HER-2-Positive Breast Cancer
Open the PDF for p95HER-2 Predicts Worse Outcome in Patients with HER-2-Positive Breast Cancer in another window
Journal Articles

ZD1839, a Specific Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor, Induces the Formation of Inactive EGFR/HER2 and EGFR/HER3 Heterodimers and Prevents Heregulin Signaling in HER2-overexpressing Breast Cancer Cells

Free
Judit Anido, Pablo Matar, Joan Albanell, Marta Guzmán, Federico Rojo, Joaquin Arribas, Steve Averbuch, Jose Baselga
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (4): 1274–1283.
Published: 01 April 2003
View articletitled, ZD1839, a Specific Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor, Induces the Formation of Inactive EGFR/HER2 and EGFR/HER3 Heterodimers and Prevents Heregulin Signaling in HER2-overexpressing Breast Cancer Cells
Open the PDF for ZD1839, a Specific Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor, Induces the Formation of Inactive EGFR/HER2 and EGFR/HER3 Heterodimers and Prevents Heregulin Signaling in HER2-overexpressing Breast Cancer Cells in another window